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To evaluate the therapeutic beneﬁt of lymphadenectomy and adjuvant therapy, in particular chemotherapy, we retrospectively
analysed survival rates and patterns of recurrence of endometrioid adenocarcinoma in 106 patients who underwent surgery
including retroperitoneal lymphadenectomy. Adjuvant chemotherapy was administered to 46 patients (42 received a platinum-
based regimen) and pelvic irradiation to 12. The 5-year survival rate of 23 patients with lymph node metastasis was worse
than that of patients without lymph node metastasis (60% vs 96%, P50.0001). Recurrence was observed in 14 patients (10
patients with chemotherapy, two with irradiation, and two without adjuvant therapy); the ﬁrst site of recurrence was in distant
sites in 12 patients; recurrence in the pelvic sidewall or exclusively in lymph nodes was not observed. The 5-year survival rate
of 18 patients with lymph node metastasis treated with chemotherapy, was 61% including all 14 with macroscopically positive
nodes and all nine with paraaortic metastasis. Of seven patients with bulky positives nodes, three patients with bulky
paraaortic nodes died of the disease, three of the four patients with bulky pelvic but without bulky paraaortic nodes had no
recurrence. In summary, lymphadenectomy may afford a survival beneﬁt via the debulking of macroscopically positive nodes,
and the predominance of distant recurrences suggests that chemotherapy is a suitable choice as an adjuvant therapy in
endometrial carcinoma after lymphadenectomy.
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In endometrial carcinoma, lymph node metastasis is one of the
most important prognostic factors for disease recurrence and death
(DiSaia et al, 1985; Lurain et al, 1991; Morrow et al, 1991);
however, the role of lymphadenectomy in the management of
endometrial carcinoma still remains controversial. Lymphadenect-
omy is recommended for predicting patients prognosis and for
tailoring postoperative therapy in many studies (Chuang et al,
1995; Kilgore et al, 1995; Blythe et al, 1997; Yokoyama et al,
1997). However, Creutzberg et al (2000) stated that lymphadenect-
omy cannot be considered a standard procedure because its beneﬁt
is unclear. Since lymphadenectomy is performed mainly with diag-
nostic intent, positive lymph nodes are often left unresected
(Creasman et al, 1987); therefore the therapeutic beneﬁt of
lymphadenectomy, which should be evaluated by resection of
macroscopically positive nodes as well as microscopically positive
nodes, is still unclear.
The majority of patients at a risk of recurrence receive adjuvant
radiotherapy following surgery. However, although pelvic radio-
therapy decreases vaginal stump recurrence it does not improve
survival (Aalders et al, 1980; Creutzberg et al, 2000), since many
patients develop distant recurrences. Recently, in some studies,
adjuvant chemotherapy has been administered to patients at a risk
of recurrence (Yokoyama et al, 1997; Larson et al, 1998).
We have been performing lymphadenectomy that removes nega-
tive and positive nodes including macroscopically enlarged nodes
with therapeutic intent on endometrial carcinoma patients. In
our institution, moreover, adjuvant chemotherapy has been
performed on patients at a high risk of recurrence. In this retro-
spective study, our objectives are to evaluate the therapeutic
beneﬁt of lymphadenectomy and adjuvant therapy, in particular
chemotherapy, by analysing survival rates and patterns of recur-
rences.
PATIENTS AND METHODS
Between 1980 and 1999, 143 women with endometrial adenocarci-
noma were treated at the Department of Obstetrics and
Gynecology, Tokyo Medical and Dental University Hospital.
Excluding patients with concomitant malignancy (eight patients
with ovarian carcinoma, one with fallopian tube carcinoma) and
histology other than endometrioid tumour (four patients), 130
patients had stage I–IV endometrioid adenocarcinoma. Of these
patients, nine had abdominal or pulmonary spread, and 15 with
stage I–III disease did not undergo lymphadenectomy. Thus, 106
patients who underwent surgery including lymphadenectomy were
studied.
All 106 patients underwent abdominal hysterectomy, bilateral
salpingo-oophorectomy, and pelvic lymphadenectomy. Systematic
pelvic lymphadenectomy is performed to remove the following
lymph nodes with surrounding fat pads: common iliac, external
iliac, internal iliac, obturator, and deep inguinal nodes. Before
1988, paraaortic nodes were dissected in patients with gross para-
aortic node swelling, and since 1988 paraaortic nodes have been
dissected in the patients at risk for paraaortic node metastasis
such as those with grossly positive pelvic and/or paraaortic nodes,
gross adnexal metastasis, high grade tumours, and deep myome-
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www.bjcancer.comtrial invasion which is determined intraoperatively by gross
inspection of a sectioned uterine corpus. Paraaortic nodes are
systematically dissected as follows: through the incision of the
posterior peritoneum at the small bowel mesentery, lymph nodes
anterior and lateral to the aorta and inferior vena cava are
removed up to the renal vessel. The total number of patients in
our study who had paraaortic node dissection was 47 (44%). Even
when grossly positive nodes were found, complete node dissection
was performed in those areas. The mean number of nodes
removed was 19 (range, 2–43) for the pelvic nodes and 7 (range,
1–24) for the paraaortic nodes. None of the patients had gross
residual disease after surgery.
All patients had endometrioid adenocarcinomas with or with-
out squamous differentiation: 67 patients (63%) with grade 1,
27 (25%) with grade 2, and 12 (11%) with grade 3 tumours.
The stages, which were deﬁned according to the 1989 Interna-
tional Federation of Gynecology and Obstetrics staging system,
of the 106 patients were as follows: stage I, 66 patients
(62%); stage II, 12 patients (11%); stage III, 27 patients
(25%); and stage IV, 1 patient (1%). The stage IV patient
had inguinal node metastasis with pelvic and paraaortic lymph
node involvement, but did not have other distant metastases.
Patients treated prior to 1989 were retrospectively staged based
on their surgical-pathologic ﬁndings; the results of peritoneal
cytology for 20 patients (19%) treated before 1988, in whom
peritoneal washing was not obtained, was considered as nega-
tive. The patients ranged in age from 27–81 years (mean, 56
years).
Adjuvant therapy was administered to 58 patients (55%). The
standard adjuvant therapy of our institution for the patients with
risk factors for recurrence, namely, deep myometrial invasion,
cervical extension, or extrauterine disease, has been chemotherapy.
From 1980 to 1983, a combination of cyclophosphamide 200 mg
body
71 and 5-ﬂuorouracil 500 mg body
71 was the preferred regi-
men, which was administered to four patients. Since 1984, ﬁve
cycles of platinum-based chemotherapy at a 4-week interval were
administered in standard doses including cisplatin at 50 mg m
72,
doxorubicin at 40–50 mg m
72 and cyclophosphamide at 400–
500 mg m
72 (CAP); patients with impaired renal function received
carboplatin instead of cisplatin. A platinum-based regimen was
administered to 42 patients, including all patients with macrosco-
pically positive nodes or paraaortic metastasis. Ten other patients
in poor health or who refused chemotherapy were irradiated with
a 50.6 Gy external beam to the whole pelvis; radiotherapy was
delivered in a daily fraction of 2.2 Gy, four times a week. Two
other patients were treated with a combination of pelvic radiother-
apy and chemotherapy. None of the patients received preoperative
radiotherapy.
Factors assessed were as follows: lymph node metastasis, size
of positive lymph nodes, non-nodal extrauterine diseases (posi-
tive peritoneal washing, and adnexal, serosal, and vaginal
involvement), sites of the ﬁrst recurrence, and survival time. In
this study, a microscopically positive lymph node was deﬁned
as a node with a size 41 cm, macroscopically positive lymph
node a node with a size 41 cm and a bulky positive node a
node with a size 42 cm. Survival time was calculated from
the date of surgery to the date of death or last contact. Survival
times of the patients who died of causes other than endometrial
carcinoma were censored at the date of death. Two patients,
with stage IIIC disease, who died with disease status unknown
(2, 19 months), were considered to have died of disease. The
median follow-up was 68 months (range, 2–233 months),
including death cases. Survival curves were estimated using the
Kaplan–Meier product-limit method and compared using the
log-rank test. The statistical analysis was performed using the
StatView software (version 4.5; Abacus Concepts Inc., Berkeley,
CA, USA).
RESULTS
Retroperitoneal lymph node metastasis was found in 23 (22%) of
106 patients: 21 (20%) in the pelvic, and nine (8%) in the paraaor-
tic region. Of the 21 patients with pelvic node metastasis, seven
(33%) had coexisting paraaortic node metastasis, including one
patient who had inguinal lymph node metastasis. Paraaortic node
metastasis without pelvic node involvement was found in two
patients.
The 5-year survival rate of patients with lymph node metastasis
was 60%, which was signiﬁcantly worse than that of the patients
without lymph node metastasis, i.e., 96% (P50.0001). In the 23
patients with lymph node metastasis, the 5-year survival rates of
the patients with pelvic node metastasis alone and that of the
patients with paraaortic node metastasis were 71% and 44%,
respectively; the difference was not statistically signiﬁcant (P=0.12).
Recurrence developed in 14 (13%) of 106 patients (Table 1). In
node-negative patients, only distant recurrences developed (the
lung in three, the liver in one; three stage IC patients and one stage
IIIB patient); retroperitoneal lymph node recurrence was not
observed. In node-positive patients, recurrences developed in
distant sites in eight patients (the liver in three, the lung in two,
the brain in two, the abdominal cavity in one), and in the vaginal
stump in two. Lymph node recurrences, which were found in the
paraaortic region, developed in two patients concomitantly with
distant metastasis (the lungs in one, and the liver in the other),
both of whom had macroscopically positive pelvic nodes. Recur-
rence exclusively in lymph nodes did not develop in any of the
patients. No pelvic sidewall recurrence was observed. Vaginal
stump recurrence developed in two patients, one treated with adju-
vant chemotherapy and the other who did not receive adjuvant
therapy; the former patient was alive without recurrence of the
disease for more than eight years after surgical resection of the
tumour and vaginal brachytherapy, but the latter patient who
received vaginal brachytherapy developed a recurrence in the lower
vagina followed by pulmonary metastases.
Of the 23 patients with lymph node metastasis, adjuvant
chemotherapy was administered to 18, including all 14 with macro-
scopically positive nodes and all nine with paraaortic node
metastasis; the 5-year survival rate of the 18 patients was 61%, and
those of the patients with pelvic node metastasis alone and the
patients with paraaortic node metastasis were 78% and 44%, respec-
tively. Five patients with either positive peritoneal washing, gross
adnexal, or serosal involvement had a signiﬁcantly worse survival rate
than 13 patients without these extrauterine diseases (20% vs 77%,
P=0.0004, Figure 1). Grade had no signiﬁcant effect on survival (5-
year survival, 83% for grade 1 vs 50% for grade 2 or 3).
All 14 patients with macroscopically positive nodes received a
platinum-based chemotherapy (Table 2). The 5-year survival rate
of patients with macroscopically positive nodes was not different
from that of patients with microscopically positive nodes (60%
vs 62%, respectively). Of the 14 patients, seven had bulky positive
node(s), and their 5-year survival rate was 43%; whereas three
patients who had bulky paraaortic nodes died of the disease, three
of four patients with bulky pelvic but without bulky paraaortic
nodes had no recurrence.
DISCUSSION
This study shows that lymphadenectomy may afford a survival
beneﬁt via the debulking of macroscopic lymph node metastases.
Moreover, the patterns of recurrence, that is, the predominance
of distant recurrences, suggests that chemotherapy is a more suita-
ble choice as an adjuvant therapy than radiotherapy in endometrial
carcinoma after lymphadenectomy.
Lymphadenectomy appears to reduce lymph node recurrence in
both patients with positive and negative nodes. Our observation
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patients with positive nodes appears to support the therapeutic
beneﬁt of lymphadenectomy. Moreover, in patients in whom
lymph node metastasis was not detected, lymphadenectomy may
have removed an unrecognised micrometastatic disease in lymph
nodes. The majority of recurrences after lymphadenectomy devel-
oped in distant sites such as the lung, liver and brain; these
recurrences may be caused by haematogenous spread that may
already have occurred at the time of surgery or could not be
prevented by dissection of the lymph nodes.
Also in patients with macroscopically positive nodes, lymphade-
nectomy may have a therapeutic beneﬁt: the survival rate of these
patients was not different from that of the patients with microsco-
pically positive nodes. Even in patients with bulky positive nodes in
the pelvic region, a favourable survival is expected by removal of
these nodes and adjuvant chemotherapy.
However, certain subsets of node-positive patients have a poor
survival: those with bulky positive paraaortic node(s). Patients with
paraaortic node involvement have been reported to have a worse 5-
year survival rate than those with pelvic node metastasis alone:
27–75% vs 67–100%, respectively (Potish et al, 1985; Corn et
al, 1992; Hicks et al, 1993; Kadar et al, 1994; Onda et al, 1997;
Yokoyama et al, 1997). In our previous study, patients with para-
aortic node metastases were at risk of pulmonary metastases
(Otsuka et al, 2002); thus, a haematogenous spread such as
pulmonary metastases developing after paraaortic node involve-
ment may reduce the survival.
Node-positive patients with either positive peritoneal cytology,
gross adnexal, or serosal involvement also have a poor survival.
This type of disease spread, namely the coexistence of lymph node
metastasis and non-nodal extrauterine diseases, may indicate a
widely metastasised disease; in these patients lymphadenectomy
may have a limited value. In contrast, if node-positive patients
do not have these non-nodal extrauterine diseases, which appears
to mean that the disease is limited to the lymphatic system,
lymphadenectomy may have a therapeutic value in combination
with an adjuvant therapy.
Considering that the majority of recurrences develop in distant
sites, chemotherapy appears to be a more suitable choice as an
adjuvant therapy than radiotherapy in patients who underwent
lymphadenectomy. Adjuvant pelvic irradiation following surgery
without lymphadenectomy only reduced the rate of vaginal stump
recurrence, but did not improve the survival rate (Aalders et al,
1980; Creutzberg et al, 2000); in patients who underwent this treat-
ment, distant metastases developing from undetected and untreated
paraaortic nodes that were located outside of the irradiation ﬁeld
may decrease their survival; paraaortic node metastases were found
in 32–78% of the patients with pelvic node involvement (Chen et
al, 1985; Morrow et al, 1991; Yokoyama et al, 1997; Onda et al,
1997; Hirahatake et al, 1997) and in 16–44% of the patients with
deep (4½) myometrial invasion (Morrow et al, 1991; Yokoyama
et al, 1997; Hirahatake et al, 1997).
Extended-ﬁeld irradiation that consists of pelvic and paraaortic
irradiation, or whole abdominal irradiation after surgery including
paraaortic with or without pelvic node sampling appears to have a
therapeutic effect on patients with positive paraaortic nodes.
However, these types of radiotherapy do not appear to be effective
for cases of distant metastases, which are the majority of recur-
rences of endometrial carcinoma. Also, these types of irradiation
frequently cause bowel complication especially after dissection of
the paraaortic nodes (Komaki et al, 1983; Rose et al, 1992; Hicks
et al, 1993).
It has not been proved that irradiation can eradicate tumour
cells in macroscopically enlarged lymph nodes. In contrast, surgical
resection of macroscopically enlarged nodes is presumed to have a
debulking effect. In cervical carcinoma, patients with macroscopic
lymph node metastasis and who have a poorer survival rate than
patients with only microscopic lymph node metastasis (Monk et
al, 1994) had improved outcomes by debulking of enlarged positive
lymph nodes (Cosin et al, 1998). Our study, like the study of Cosin
et al, demonstrated similar survivals for patients with completely
resected lymph nodes, whether they were microscopically or
macroscopically positive. In patients treated by adjuvant
chemotherapy alone, pelvic recurrence is common after lymph
node sampling or in the absence of lymphadenectomy (Mundt et
al, 2001); in contrast, no pelvic sidewall recurrence was observed
in our study, which included patients with bulky positive nodes.
This suggests that after lymphadenectomy, irradiation to the whole
pelvis may not be required.
Chemotherapy has been given as the standard adjuvant ther-
apy in our institution; in endometrial carcinoma, response
rates ranging from 38 to 76% have been reported with regimens
of cisplatin, doxorubicin, with or without cyclophosphamide
C
l
i
n
i
c
a
l
Table 1 Recurrence patterns by nodal status and adjuvant therapy
Vaginal stump Distant sites
a
Lymph node mestastasis
Negative 0 4
Positive 2 8
Adjuvant therapy
Chemotherapy 1 9
Pelvic radiation 0 2
b
No adjuvant therapy 1 1
aLung, liver, brain, and abdominal cavity.
bIncluding one patient treated with a combi-
nation of chemotherapy and pelvic radiation.
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Figure 1 Survival of patients with lymph node metastasis: patients with
either positive peritoneal washing, gross adnexal involvement, or serosal in-
volvement (A) vs patients without these extrauterine diseases (B).
Table 2 Adjuvant therapy
Pelvic No adjuvant
Chemotherapy irradiation therapy
Lymph node metastasis
Negative 28 9 (1) 46
Positive
Node size 41c m 4
a 3 (1) 2
b
Node size 41c m 1 4 0 0
Number in brackets: patient treated with a combination of chemotherapy and pelvic
irradiation.
aIncluding one patient treated with non-platinum-based chemotherapy.
bOne patient refused adjuvant therapy, and the other was old age (81 years).
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chemotherapy-treated patients with pelvic node metastasis alone
and those with paraaortic node metastasis were 78 and 44%,
respectively. These survival rates favourably compare with
reported survival rates of patients treated with adjuvant radio-
therapy; 67–82% in patients with pelvic node metastasis alone
and 27–58% in those with paraaortic node metastasis (Potish
et al, 1985; Corn et al, 1992; Hicks et al, 1993; Kadar et al,
1994; Blythe et al, 1997).
We believe that pelvic lymphadenectomy should be performed
in all patients with endometrial carcinoma, since approximately
20% of patients have pelvic lymph node metastasis (Hirahatake
et al, 1997), including those with superﬁcial invasion and low grade
tumours. In contrast, paraaortic lymph nodes that were positive in
approximately 10% of patients should be dissected only in patients
at a high risk of metastases; Morrow et al (1991) noted that 98% of
paraaortic node metastases were found in patients with either
grossly positive pelvic nodes, grossly positive adnexal metastases,
or outer one third myometrial invasion. In the present study, all
patients with paraaortic node metastases had deep (4½) myome-
trial invasion.
The results of the present study show the therapeutic beneﬁt of
lymphadenectomy and adjuvant chemotherapy. However, distant
recurrences may still develop in certain subsets of node-positive
and node-negative patients. Further investigation to develop more
potent systemic adjuvant treatments is needed.
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